New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.At the Cardiometabolic Health Congress in ...

Following the FDA’s release of a guidance requesting more diversity in pulse oximeter testing, the number of clearance ...

A new electronic health record-based model accurately predicted risk for gastric cancer using demographic, behavioral and ...

The addition of camrelizumab to platinum-containing intensive neoadjuvant chemotherapy improved pathologic complete response ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

Women diagnosed with advanced breast cancer appeared more likely than those with earlier-stage breast cancer to have ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

A once-daily dose of ivarmacitinib reduced disease activity and improved function among patients with rheumatoid arthritis ...

After 50 years of life, people who were born preterm had lower odds for some cardiovascular outcomes and similar odds for ...

JJ is a 75-year-old man who presents to the office after his wife made an appointment for him this morning for evaluation of ...

The FDA cleared the Epithelial Thickness Module for the Anterion cornea app from Heidelberg Engineering, according to a press ...

A significant proportion of new cases of CVD and diabetes globally can be attributed to the consumption of sugar-sweetened beverages. , according to a new study published in Nature Medicine. cases of ...